160 related articles for article (PubMed ID: 9821107)
1. Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model.
Pollina J; Plunkett RJ; Ciesielski MJ; Lis A; Barone TA; Greenberg SJ; Fenstermaker RA
J Neurooncol; 1998 Sep; 39(3):217-25. PubMed ID: 9821107
[TBL] [Abstract][Full Text] [Related]
2. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
3. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model.
Kaiser MG; Parsa AT; Fine RL; Hall JS; Chakrabarti I; Bruce JN
Neurosurgery; 2000 Dec; 47(6):1391-8; discussion 1398-9. PubMed ID: 11126910
[TBL] [Abstract][Full Text] [Related]
4. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
Lamond JP; Mehta MP; Boothman DA
J Neurooncol; 1996 Oct; 30(1):1-6. PubMed ID: 8864997
[TBL] [Abstract][Full Text] [Related]
5. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
Saito R; Krauze MT; Noble CO; Drummond DC; Kirpotin DB; Berger MS; Park JW; Bankiewicz KS
Neuro Oncol; 2006 Jul; 8(3):205-14. PubMed ID: 16723630
[TBL] [Abstract][Full Text] [Related]
6. Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
Yamashita Y; Krauze MT; Kawaguchi T; Noble CO; Drummond DC; Park JW; Bankiewicz KS
Neuro Oncol; 2007 Jan; 9(1):20-8. PubMed ID: 17018695
[TBL] [Abstract][Full Text] [Related]
7. Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump.
Sonabend AM; Stuart RM; Yun J; Yanagihara T; Mohajed H; Dashnaw S; Bruce SS; Brown T; Romanov A; Sebastian M; Arias-Mendoza F; Bagiella E; Canoll P; Bruce JN
Neuro Oncol; 2011 Aug; 13(8):886-93. PubMed ID: 21750007
[TBL] [Abstract][Full Text] [Related]
8. Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.
Grahn AY; Bankiewicz KS; Dugich-Djordjevic M; Bringas JR; Hadaczek P; Johnson GA; Eastman S; Luz M
J Neurooncol; 2009 Nov; 95(2):185-197. PubMed ID: 19466380
[TBL] [Abstract][Full Text] [Related]
9. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
[TBL] [Abstract][Full Text] [Related]
10. Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Kogias E; Osterberg N; Baumer B; Psarras N; Koentges C; Papazoglou A; Saavedra JE; Keefer LK; Weyerbrock A
Int J Cancer; 2012 Mar; 130(5):1184-94. PubMed ID: 21455987
[TBL] [Abstract][Full Text] [Related]
11. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
Wang W; Ghandi A; Liebes L; Louie SG; Hofman FM; Schönthal AH; Chen TC
J Neurosurg; 2011 Mar; 114(3):689-94. PubMed ID: 20415520
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of topotecan for pediatric central nervous system tumors.
Blaney SM; Phillips PC; Packer RJ; Heideman RL; Berg SL; Adamson PC; Allen JC; Sallan SE; Jakacki RI; Lange BJ; Reaman GH; Horowitz ME; Poplack DG; Balis FM
Cancer; 1996 Aug; 78(3):527-31. PubMed ID: 8697400
[TBL] [Abstract][Full Text] [Related]
13. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
15. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus.
Ito H; Aoki H; Kühnel F; Kondo Y; Kubicka S; Wirth T; Iwado E; Iwamaru A; Fujiwara K; Hess KR; Lang FF; Sawaya R; Kondo S
J Natl Cancer Inst; 2006 May; 98(9):625-36. PubMed ID: 16670388
[TBL] [Abstract][Full Text] [Related]
16. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
[TBL] [Abstract][Full Text] [Related]
17. Topotecan can compensate for protracted radiation treatment time effects in high grade glioma xenografts.
Pinel S; Chastagner P; Merlin JL; Marchal C; Taghian A; Barberi-Heyob M
J Neurooncol; 2006 Jan; 76(1):31-8. PubMed ID: 16311843
[TBL] [Abstract][Full Text] [Related]
18. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.
Price A; Shi Q; Morris D; Wilcox ME; Brasher PM; Rewcastle NB; Shalinsky D; Zou H; Appelt K; Johnston RN; Yong VW; Edwards D; Forsyth P
Clin Cancer Res; 1999 Apr; 5(4):845-54. PubMed ID: 10213221
[TBL] [Abstract][Full Text] [Related]
19. Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9.
Luther N; Cheung NK; Dunkel IJ; Fraser JF; Edgar MA; Gutin PH; Souweidane MM
Neurosurgery; 2008 Dec; 63(6):1166-74; discussion 1174. PubMed ID: 19057330
[TBL] [Abstract][Full Text] [Related]
20. The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model.
Tanriover N; Ulu MO; Sanus GZ; Bilir A; Canbeyli R; Oz B; Akar Z; Kuday C
Neurol Res; 2008 Jun; 30(5):511-7. PubMed ID: 18953742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
